CoA – Certificate of Analysis

Certificate of Analysis (CoA) is an official document issued by the manufacturer of the medicinal product. It contains information on some critical quality characteristics of the medicine. Click here to learn more. CoA’s are available only for some medicines and limited batches. Customers can order the medicinal product CoA together with the aliquots of the same batch.

Filters Sort results
Certificate of Analysis(from reference drug manufacturer)
Batch Number
Expiry Date
Price
CoA – Avastin | Bevacizumab | VEGF-A | B8800H28
B8800H28
03/2021
150,00 
CoA – Humira | Adalimumab | TNF-α | 02006LX02
02006LX02
01/2021
150,00 
CoA – Humira | Adalimumab | TNF-α | 040309A07
040309A07
03/2021
150,00 
CoA – Humira | Adalimumab | TNF-α | 70225XH07
70225XH07
09/2018
150,00 
CoA – Humira | Adalimumab | TNF-α | 73254XH03
73254XH03
12/2018
150,00 
CoA – Humira | Adalimumab | TNF-α | 76287XH07
76287XH07
03/2019
150,00 
CoA – Humira | Adalimumab | TNF-α | 76287XH11
76287XH11
03/2019
150,00 
CoA – Humira | Adalimumab | TNF-α | 80315XH04
80315XH04
07/2019
150,00 
CoA – Humira | Adalimumab | TNF-α | 85364XH07
85364XH07
12/2019
150,00 
CoA – Humira | Adalimumab | TNF-α | 88400XH01
88400XH01
03/2020
150,00 
CoA – Perjeta | Pertuzumab | HER2 | H0332H02
H0332H02
11/2020
150,00 
CoA – Skyrizi | Risankizumab | IL23 | 1124728
1124728
06/2021
150,00 
CoA – Stelara | Ustekinumab | IL-12 | JKS2Gxx
inquire for details
10/2022
150,00 
CoA – Stelara | Ustekinumab | IL-12 | JKS2Gxy
inquire for details
10/2022
150,00 
CoA – Stelara | Ustekinumab | IL-12 | KCS11xx
inquire for details
02/2023
150,00 
CoA – Synagis | Palivizumab | RSV protein F | 382291
382291
04/2019
150,00 
CoA – Synagis | Palivizumab | RSV protein F | 382445
382445
06/2019
150,00 
CoA – Synagis | Palivizumab | RSV protein F | 382615
382615
10/2019
150,00 
CoA – Synagis | Palivizumab | RSV protein F | 382683
382683
02/2020
150,00 
CoA – Synagis | Palivizumab | RSV protein F | 382835
382835
08/2020
150,00 
CoA – Tecentriq | Atezolizumab | PD-L1 | B0006B01
B0006B01
03/2022
150,00 
CoA – Yervoy | Ipilimumab | CD152 / CTLA4 | ABE0468
ABE0468
08/2021
150,00